Ann Arbor, Michigan
Cancer clinical trials in Ann Arbor, MI
145 cancer studies are recruiting participants at sites in Ann Arbor as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Ann Arbor at a glance
- 145 studies are recruiting at a site in Ann Arbor.
- By phase: Phase 1 (16), Phase 1/2 (11), Phase 2 (43), Phase 2/3 (1), Phase 3 (45), Phase 4 (1), No phase (9), Observational (19). Studies of devices and behavioral approaches have no phase.
- By sponsor: university, hospital or other (75), industry (46), government (24).
- By research area: Lymphoma (35), Breast Cancer (34), Lung Cancer (31), Prostate Cancer (26), Pancreatic Cancer (11), Melanoma (8).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Ann Arbor
Basic details from each study's public record (the 30 most recently updated of 145). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Saint Joseph Mercy Hospital · University of Michigan Comprehensive Cancer Center
- Registry record
- NCT03418961 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
- Registry record
- NCT06058377 · updated
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Saint Joseph Mercy Hospital
- Registry record
- NCT03723928 · updated
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- ALX Oncology Inc.
- Study site
- University of Michigan Rogel Cancer Center
- Registry record
- NCT07007559 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Lung cancer studies recruiting in Ann Arbor
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Novelty Nobility, Inc.
- Study site
- University of Michigan Hospitals
- Registry record
- NCT06805825 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT04267848 · updated
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
- Observational
- All ages
- All sexes
- Sponsor
- Lung Cancer Mutation Consortium
- Study site
- University of Michigan
- Registry record
- NCT04712877 · updated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Michigan Rogel Cancer Center
- Registry record
- NCT06498635 · updated
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- VA Ann Arbor Healthcare System ( Site 0019)
- Registry record
- NCT07221474 · updated
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Study site
- University of Michigan
- Registry record
- NCT07002034 · updated
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Michigan
- Registry record
- NCT07020221 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Prostate cancer studies recruiting in Ann Arbor
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
- Phase 2
- Ages 18 and older
- Male participants
- Sponsor
- VA Office of Research and Development
- Study site
- VA Ann Arbor Healthcare System, Ann Arbor, MI
- Registry record
- NCT04038502 · updated
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT03866382 · updated
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
- Observational
- Ages 40 to 80
- Male participants
- Sponsor
- University of Michigan Rogel Cancer Center
- Study site
- University of Michigan Rogel Cancer Center
- Registry record
- NCT05965180 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Melanoma studies recruiting in Ann Arbor
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
- Registry record
- NCT05136196 · updated
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University of Michigan
- Registry record
- NCT06246916 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Lymphoma studies recruiting in Ann Arbor
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545)
- Registry record
- NCT06717347 · updated
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT03739814 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- C S Mott Children's Hospital
- Registry record
- NCT04546399 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- C S Mott Children's Hospital · Trinity Health Saint Joseph Mercy Hospital Ann Arbor
- Registry record
- NCT05675410 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- University of Michigan Rogel Cancer Center
- Registry record
- NCT06337318 · updated
Living Well With Lymphoma
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- University of Michigan Rogel Cancer Center
- Study site
- University of Michigan
- Registry record
- NCT06047626 · updated
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- University of Michigan Health System
- Registry record
- NCT06084936 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Ann Arbor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Phase 2
- Ages 12 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University of Michigan ( Site 0126)
- Registry record
- NCT04924075 · updated
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US006
- Registry record
- NCT07522073 · updated
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Verastem, Inc.
- Study site
- University of Michigan
- Registry record
- NCT07644559 · updated
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor · University of Michigan Rogel Cancer Center
- Registry record
- NCT04858334 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Ann Arbor, MI on ClinicalTrials.gov.
Ask about studies near Ann Arbor
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Michigan
All Michigan locations
390 studies recruiting across 66 cities.
Detroit
164 studies recruiting.
Grand Rapids
155 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections